|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 65 Hayden Avenue |
Address2 | |
City | Lexington |
State | MA |
Zip Code | 02421 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 40026226-75
|
||||||||
|
6. House ID# 398750000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mark T. Battaglini, Esq., Vice President, Government Affairs |
Date | 07/20/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act,
2013.
Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation;
FDA Appropriations. Support protection of US law regarding biosimilars (12 years data exclusivity).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
FDA legislation and regulatory implementation issues
H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act (S.1734)
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub.
L. 111-152)
Congressional deficit reduction negotiations and Deficit Reduction Commission, following passage of the Budget Control Act of 2011 (P.L. 112-25).
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act; H.R. 5651, Food and Drug Administration Reform Act of 2012,
S.3187, Food and Drug Administration Safety and Innovation Act; issues pertaining to antibiotic incentives, drug safety pedigree, and drug supply chain.
Medical research.
Antibiotic resistance issues.
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act
Address concerns regarding uncertainty and unpredictability of FDA drug and device regulatory environment. Support drug and device user fee legislation. Address concerns with Medicare Independent Payment Advisory Board (IPAB).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare home infusion and reimbursement issues.
340B issues.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 5194, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 5624, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
Address concerns with Medicare Independent Payment Advisory Board (IPAB).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 2292, Patients' FDA Act
S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012.
S. 1734 / H.R. 2182, Generating Antiobiotic Incentives Now Act (GAIN Act) - incentives for development of products to treat
antibiotic-resistant infections;
S. 3187, Food and Drug Administration Safety and Innovation Act - incentives for development of products to treat
antibiotic-resistant infections;
ADDENDUM for General Lobbying Issue Area: PHA - Pharmacy
H.R. 5651, Food and Drug Administration Reform Act of 2012 - incentives for development of products to treat
antibiotic-resistant infections
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Support repeal of medical device tax. Support extension of R&D tax credit.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |